The real-world outcomes of multiple myeloma patients treated with daratumumab.

Agoston Gyula SzaboTobias Wirenfeldt KlausenMette Bøegh LevringBirgitte PreissCarsten HellebergMarie Fredslund BreinholtNiels Emil Ulrich HermansenLise Mette Rahbek GjerdrumSøren Thorgaard BønløkkeKatrine NielsenEigil KjeldsenKatrine Fladeland IversenElena Manuela TeodorescuMarveh DokhiEva KurtCasper StrandholdtMette Klarskov AndersenAnnette Juul Vangsted

Published in: PloS one (2021)

The real-world outcomes of multiple myeloma patients treated with daratumumab are worse than the results of clinical trials. Outcomes achieved with daratumumab were best when daratumumab was used in combination with IMIDs and in early LOT. Patients with high-risk CA had worse outcomes, but patients with amp1q had similar outcomes to standard-risk patients.

Keyphrases

multiple myeloma
clinical trial
end stage renal disease
chronic kidney disease
type diabetes
newly diagnosed
metabolic syndrome
adipose tissue
study protocol
insulin resistance
placebo controlled